News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
742,721 Results
Type
Article (43862)
Company Profile (318)
Press Release (698528)
Multimedia
Podcasts (118)
Webinars (19)
Section
Business (211008)
Career Advice (2109)
Deals (36765)
Drug Delivery (125)
Drug Development (83436)
Employer Resources (176)
FDA (16833)
Job Trends (15503)
News (357410)
Policy (34135)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2616)
Accelerated approval (34)
Adcomms (26)
Allergies (152)
Alliances (51584)
ALS (177)
Alzheimer's disease (1702)
Antibody-drug conjugate (ADC) (332)
Approvals (17102)
Artificial intelligence (548)
Autoimmune disease (163)
Automation (43)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (200)
Biotechnology (188)
Bladder cancer (161)
Brain cancer (61)
Breast cancer (656)
Cancer (4969)
Cardiovascular disease (423)
Career advice (1788)
Career pathing (37)
CAR-T (288)
CDC (51)
Celiac Disease (2)
Cell therapy (766)
Cervical cancer (37)
Clinical research (71253)
Collaboration (1789)
Company closure (4)
Compensation (1190)
Complete response letters (65)
COVID-19 (2789)
CRISPR (99)
C-suite (894)
Cystic fibrosis (148)
Data (6385)
Decentralized trials (2)
Denatured (36)
Depression (139)
Diabetes (512)
Diagnostics (6801)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (266)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (236)
Earnings (92030)
Editorial (62)
Employer branding (21)
Employer resources (155)
Events (120493)
Executive appointments (1012)
FDA (20040)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1504)
Gene editing (207)
Generative AI (46)
Gene therapy (621)
GLP-1 (1030)
Government (4812)
Grass and pollen (7)
Guidances (385)
Healthcare (19069)
HIV (62)
Huntington's disease (46)
IgA nephropathy (86)
Immunology and inflammation (266)
Immuno-oncology (63)
Indications (123)
Infectious disease (3069)
Inflammatory bowel disease (202)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (260)
Interviews (327)
IPO (16922)
IRA (57)
Job creations (4070)
Job search strategy (1498)
JPM (64)
Kidney cancer (17)
Labor market (86)
Layoffs (576)
Leadership (34)
Legal (8425)
Liver cancer (92)
Longevity (16)
Lung cancer (668)
Lymphoma (385)
Machine learning (43)
Management (60)
Manufacturing (842)
MASH (172)
Medical device (13869)
Medtech (13928)
Mergers & acquisitions (20920)
Metabolic disorders (1332)
Multiple sclerosis (164)
NASH (17)
Neurodegenerative disease (331)
Neuropsychiatric disorders (93)
Neuroscience (2987)
Neurotech (1)
NextGen: Class of 2026 (6645)
Non-profit (4563)
Now hiring (68)
Obesity (634)
Opinion (291)
Ovarian cancer (168)
Pain (220)
Pancreatic cancer (235)
Parkinson's disease (288)
Partnered (34)
Patents (520)
Patient recruitment (504)
Peanut (61)
People (60977)
Pharmaceutical (90)
Pharmacy benefit managers (32)
Phase 1 (22119)
Phase 2 (31330)
Phase 3 (23474)
Pipeline (5599)
Policy (307)
Postmarket research (2655)
Preclinical (9393)
Press Release (68)
Prostate cancer (249)
Psychedelics (50)
Radiopharmaceuticals (291)
Rare diseases (892)
Real estate (6306)
Recruiting (72)
Regulatory (25486)
Reports (53)
Research institute (2442)
Resumes & cover letters (361)
Rett syndrome (27)
RNA editing (17)
RSV (81)
Schizophrenia (159)
Series A (250)
Series B (194)
Service/supplier (11)
Sickle cell disease (103)
Special edition (25)
Spinal muscular atrophy (160)
Sponsored (43)
Startups (3766)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (96)
The Weekly (79)
Vaccines (1044)
Venture capital (91)
Weight loss (416)
Women's health (97)
Worklife (18)
Date
Today (158)
Last 7 days (715)
Last 30 days (2556)
Last 365 days (30432)
2026 (4355)
2025 (30691)
2024 (35769)
2023 (40630)
2022 (51799)
2021 (56329)
2020 (54791)
2019 (47398)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27632)
2012 (29731)
2011 (30488)
2010 (28497)
Location
Africa (801)
Alabama (85)
Alaska (7)
Arizona (319)
Arkansas (15)
Asia (42182)
Australia (6756)
California (11545)
Canada (3349)
China (1149)
Colorado (486)
Connecticut (489)
Delaware (345)
Europe (90497)
Florida (1731)
Georgia (363)
Hawaii (3)
Idaho (61)
Illinois (893)
India (73)
Indiana (540)
Iowa (22)
Japan (449)
Kansas (127)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1413)
Massachusetts (8300)
Michigan (332)
Minnesota (635)
Mississippi (5)
Missouri (129)
Montana (32)
Nebraska (28)
Nevada (125)
New Hampshire (79)
New Jersey (3065)
New Mexico (29)
New York (3038)
North Carolina (1496)
North Dakota (8)
Northern California (5647)
Ohio (343)
Oklahoma (22)
Oregon (46)
Pennsylvania (2338)
Puerto Rico (24)
Rhode Island (48)
South America (1176)
South Carolina (69)
South Dakota (1)
Southern California (4502)
Tennessee (178)
Texas (1777)
United States (41003)
Utah (346)
Vermont (1)
Virginia (282)
Washington D.C. (81)
Washington State (941)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
742,721 Results for "amylin pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026
Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.
February 6, 2026
·
4 min read
·
Mark Zipkin
Press Releases
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
February 11, 2026
·
4 min read
Obesity
Obesity Late-Comer AbbVie Inks up to $2.2B Amylin Deal With Gubra
AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.
March 3, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
December 19, 2025
·
9 min read
Press Releases
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
December 18, 2025
·
7 min read
Press Releases
Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study
January 8, 2026
·
5 min read
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
November 6, 2025
·
3 min read
·
Heather McKenzie
Press Releases
Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
November 7, 2025
·
7 min read
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
October 30, 2025
·
5 min read
Weight loss
Amylin Commands Weight Loss Attention as Industry Anticipates Novo’s Phase III CagriSema Readout
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality weight loss with a cleaner tolerability profile.
December 4, 2024
·
3 min read
·
Tristan Manalac
1 of 74,273
Next
